

- How much has CVD mortality decreased in the U.S. over the past 10 years?
 - 12 percent
 - 20 percent
 - 33 percent
 - 45 percent
- ST elevation refers to all of the following EXCEPT:
 - an acute event
 - acute rupture of a noncritical lesion
 - an inflammatory response
 - slow decrease of luminal diameter of coronary artery
- The treatment for hyperhomocysteinemia as a possible risk for CVD is:
 - folic acid
 - vitamin D
 - vitamin E
 - omega 3 acids
- Evidence to support treatment to decrease levels of homocysteine as a heart disease risk factor:
 - has not been found
 - has shown positive results in a 12-study meta-analysis
 - has produced two studies that found harmful side effects to treatment
 - is minimal, but most cardiologists support its use
- C-reactive protein levels:
 - should be ordered annually for all patients with 10 percent CVD risk
 - have been studied as a marker for subtle vascular inflammation in CVD
 - are not predictive diagnostic cardiac markers, according to AHA guidelines
 - are not effective in monitoring CVD treatment modalities
- Which of the following therapies has been shown to increase C-reactive protein levels?
 - insulin
 - beta blockers
 - hormone replacement
 - coumadin
- Lipoprotein(a) levels should be ordered for patients:
 - with elevated lipidemias
 - with established CVD but no identifiable dyslipidemias
 - being treated for dyslipidemias with statins
 - receiving Bezalip as treatment for elevated levels
- Lipoprotein(a):
 - is a modified form of HDL
 - helps to dissolve blood clots
 - competes with plasminogen and promotes coagulation
 - levels greater than 5 mg/dL are considered high
- According to the National Heart, Lung and Blood Institute and its Adult Treatment Panel III, all of the following are risk factors for CVD EXCEPT:
 - advanced age
 - low HDL levels
 - first-degree family history
 - smoking

- Current clinical recommendations regarding the use of novel cardiac markers include:
 - Homocysteine and CRP testing should be done on all patients with CVD.
 - All of the novel cardiac markers available today are not risk-benefit cost-effective.
 - Before ordering and novel cardiac markers, a lipidologist should be consulted.
 - Patients with CVD should be tested for homocysteine, CRP and lipoprotein (a) as an adjunct to the established Framingham criteria.

Evaluation

- I can state statistics relating to cardiovascular disease (CVD) and explain current CVD theory and risk factor prediction.
 - strongly agree
 - agree
 - neutral
 - disagree
 - strongly disagree
- I can define homocysteine, explain its effects on CVD and discuss treatment options for elevated homocysteine.
 - strongly agree
 - agree
 - neutral
 - disagree
 - strongly disagree
- I can define C-reactive protein (CRP), explain its effects on CVD and discuss treatment options for elevated CRP.
 - strongly agree
 - agree
 - neutral
 - disagree
 - strongly disagree
- I can define lipoprotein(a), explain its effects on CVD and discuss treatment options.
 - strongly agree
 - agree
 - neutral
 - disagree
 - strongly disagree
- The objectives relate to the overall goal of the article.
 - strongly agree
 - agree
 - neutral
 - disagree
 - strongly disagree
- The article is well-written and logically organized, and defines terms adequately.
 - strongly agree
 - agree
 - neutral
 - disagree
 - strongly disagree

Cardiac Markers

Earn 1 Contact Hour NOW!

Registration/Answer Form #346

LEARNER FEEDBACK QUESTIONS

- A B C D
- A B C D
- A B C D
- A B C D
- A B C D
- A B C D
- A B C D
- A B C D
- A B C D
- A B C D

EVALUATION

- A B C D E
- A B C D E
- A B C D E
- A B C D E
- A B C D E
- A B C D E


How many minutes did you need to complete this CE offering?

Minutes: _____

Before November 22, 2012, complete the multiple choice questions by circling the correct answer and mail or fax to: *ADVANCE for Nurses*, Learning Scope, 2900 Horizon Dr., King of Prussia, PA 19406; 610-278-1426.

CUSTOMER INFORMATION

For accuracy, please print clearly. (N05)



Subscription #

Name: _____
 Street Address: _____
 City: _____ State: _____ Zip: _____
 Daytime Phone: _____
 E-mail Address: _____
 License No. (FL required): _____

PAYMENT \$8

Make check (any checks returned for non-sufficient funds will be assessed a \$25 service fee) or money order payable to Merion Publications Learning Scope, 2900 Horizon Dr., King of Prussia, PA 19406, or pay by credit card:

Name of Cardholder: _____
 Credit Card No.: _____
 Exp. Date: _____
 American Express Visa MasterCard Discover

THIS OFFERING EXPIRES IN 2 YEARS:
 NOVEMBER 22, 2012

Keep ADVANCE Coming!

This may be only a trial copy or it may be time to renew. You won't continue to receive *ADVANCE for Nurses* unless you contact us for your FREE subscription.

- YES!** I am a Nurse, sign me up!
- I prefer to receive a **PRINT SUBSCRIPTION.**
- I prefer to receive the **DIGITAL EDITION.** (e-mail address required below)
- I prefer to receive **BOTH** a print and digital edition. (e-mail address required below)

Date: _____ Signature (required): _____

E-mail: _____

JOB TITLE that best describes your position (fill in just one circle completely)

RN

- Director of Nursing
- Manager/Supervisor
- Nursing Administrator
- Nursing Faculty
- Private Practice
- Staff Development
- Staff Nurse
- Program Director

Nursing School Student

- RN
- LPN
- Grad. date ____/____/____
- Senior
- Non-Senior (Digital Only)
- Nursing School:

LPN

- Manager/Supervisor
- Nursing Administrator
- Nursing Faculty
- Private Practice
- Staff Development
- Staff Nurse

PRACTICE SETTING that best describes your position (fill in just one circle completely)

- | | | | |
|---|---|--|--|
| <input type="radio"/> Ambulatory | <input type="radio"/> Geriatrics/LTC | <input type="radio"/> Med/Surg | <input type="radio"/> Rehab |
| <input type="radio"/> Cardiac | <input type="radio"/> Gynecology | <input type="radio"/> MR/DD | <input type="radio"/> Research |
| <input type="radio"/> Case Management | <input type="radio"/> Home Health | <input type="radio"/> Nursing/Clinical Informatics | <input type="radio"/> Sales/Marketing |
| <input type="radio"/> Chemical Dependency | <input type="radio"/> Hospice | <input type="radio"/> Occupational Health | <input type="radio"/> School Nurse |
| <input type="radio"/> Clinical Specialist | <input type="radio"/> ICU | <input type="radio"/> Office | <input type="radio"/> Student |
| <input type="radio"/> Critical Care | <input type="radio"/> Infection Control | <input type="radio"/> Oncology | <input type="radio"/> Subacute |
| <input type="radio"/> CRNA | <input type="radio"/> IV Therapy | <input type="radio"/> OR/PACU | <input type="radio"/> Support Staffing |
| <input type="radio"/> Dermatology | <input type="radio"/> Managed Care | <input type="radio"/> Orthopedics | <input type="radio"/> Travel Nursing |
| <input type="radio"/> Dialysis | <input type="radio"/> Managerial/ | <input type="radio"/> Pediatrics | <input type="radio"/> UR/QA |
| <input type="radio"/> Education | <input type="radio"/> Administrative | <input type="radio"/> Psychiatric | |
| <input type="radio"/> ED/ER | <input type="radio"/> Maternal/Child | <input type="radio"/> Public Health | |

N05